CN Patent

CN110294761B — 作为Trk激酶抑制剂的取代的吡唑并[1,5-a]嘧啶化合物

Assigned to Nanjing Leizheng Pharmaceutical Technology Co ltd · Expires 2020-09-08 · 6y expired

What this patent protects

本发明涉及一种作为Trk激酶抑制剂的取代的吡唑并[1,5‑a]嘧啶化合物，或其药学上可接受的盐、药物组合物以及用途。所述具有通式(I)结构的吡唑并[1,5‑a]嘧啶衍生物具有良好Trk家族蛋白酪氨酸激酶抑制活性和代谢稳定性。

USPTO Abstract

本发明涉及一种作为Trk激酶抑制剂的取代的吡唑并[1,5‑a]嘧啶化合物，或其药学上可接受的盐、药物组合物以及用途。所述具有通式(I)结构的吡唑并[1,5‑a]嘧啶衍生物具有良好Trk家族蛋白酪氨酸激酶抑制活性和代谢稳定性。

Drugs covered by this patent

Patent Metadata

Patent number
CN110294761B
Jurisdiction
CN
Classification
—
Expires
2020-09-08
Drug substance claim
No
Drug product claim
No
Assignee
Nanjing Leizheng Pharmaceutical Technology Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.